Bristol Myers Squibb (NYSE: BMY) has announced that it will present research findings from its comprehensive cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, scheduled for August 30 – September 2, 2024, in London, England. The presentations will feature long-term extension data assessing the efficacy and safety of CAMZYOS® (mavacamten) over 180 weeks (3.5 years) in treating New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Additionally, data from the BMS-Pfizer Alliance on ELIQUIS® (apixaban) and the BMS-Johnson & Johnson Collaboration on milvexian will be showcased.
“With the data we’re presenting from our cardiovascular franchise at this year’s ESC Congress, we continue to emphasize our deep commitment to improving the lives of patients affected by cardiovascular diseases,” said Roland Chen, MD, Senior Vice President and Head of Immunology, Cardiovascular & Neuroscience (ICN) Development at Bristol Myers Squibb. “We are eager to demonstrate our progress in developing medicines for anticoagulation and thrombosis management, as well as for treating obstructive HCM, at the upcoming conference.”
Key presentations will include:
- An oral presentation highlighting the long-term efficacy and safety of CAMZYOS in NYHA class II-III obstructive HCM over 180 weeks, marking an unprecedented follow-up period for patients using the first and only approved cardiac myosin inhibitor for oHCM (EXPLORER Ph3 MAVA LTE study).
- A moderated poster presentation exploring the relationship between key pharmacodynamic biomarkers of coagulation and systemic milvexian exposure in patients from the AXIOMATIC-TKR study.
- A moderated poster presentation discussing gender and racial differences in clinical outcomes among Medicare beneficiaries with non-valvular atrial fibrillation (NVAF) treated with oral anticoagulants, including ELIQUIS.
About the Bristol Myers Squibb-Johnson & Johnson Collaboration
Bristol Myers Squibb and Johnson & Johnson, two unsurpassed leaders in cardiovascular care, are determined to close the gap in unmet needs in thrombosis management by overcoming the limits of today’s treatments. The collaboration to develop and commercialize milvexian aims to leverage the combined scientific expertise and world-class commercial capabilities of each company, to improve patient outcomes. The alliance is uniquely equipped to deliver on the promise of FXIa inhibitors and is working diligently to ensure cutting-edge safe and effective treatment options are available for patients.
